ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2554

Validation of a Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus in a Confirmatory Cohort

Melissa Munroe1, Derek Blankenship2, Daniele DeFreese2, Adrian Holloway2, Mohan Purushothaman2, Wade DeJager3, Susan Macwana3, Joel Guthridge3, Stan Kamp3, Nancy Redinger3, Teresa Aberle3, Eliza Chakravarty3, Cristina Arriens4, Yanfeng Li5, Hu Zeng5, Stephanie Dezzutti6, Peter Izmirly7, Uma Thanarajasingam5, Diane L. Kamen6, Jill Buyon8, Judith James3 and Eldon Jupe2, 1Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, 2Progentec Diagnostics, Inc., Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, 5Mayo Clinic, Rochester, MN, 6Medical University of South Carolina, Charleston, SC, 7New York University School of Medicine, New York, NY, 8NYU Grossman School of Medicine, New York, NY

Meeting: ACR Convergence 2023

Keywords: chemokines, cytokines, Disease Activity, prognostic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Disease Activity

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: SLE is marked by immune dysregulation linked to varied clinical disease activity. Using a unique confirmatory cohort of SLE patients, this study seeks to validate a recently refined Lupus Flare Risk Index (L-FRI; Munroe et al. Arthritis Rheumatol. 2023) reflecting altered immunity prior to clinical disease flare.

Methods: The L-FRI is the sum of log-transformed, standardized immune mediators, weighted by the Spearman r correlation coefficient for each preflare/prenonflare analyte vs. subsequent flare/nonflare hSLEDAI disease activity (flare is defined by the SELENA-SLEDAI Flare Index). SLE-associated plasma mediators (n=11) were evaluated by microfluidic immunoassay in 52 preflare and 52 prenonflare samples from patients with classified SLE. Hybrid SLEDAI (hSLEDAI) scores, clinical features, medication usage, and the presence of SLE-associated autoantibody (AutoAb) specificities, including dsDNA, chromatin, Ro/SSA, La/SSB, Sm, SmRNP, and RNP, were also compared at preflare (105 ± 62 days prior to flare) vs. prenonflare (105 ± 55 days prior to nonflare) time points. Data from this validation cohort were compared to development and merged development/validation cohorts.

Results: This validation (Val) cohort is enriched for African American (AA) SLE patients (44% preflare, 48% prenonflare vs. 11% preflare, 15% prenonflare in the development [Dev] cohort), with an associated increase in preflare hSLEDAI scores (4.0±3.4 preflare, 1.9±2.2 prenonflare, p=0.0004 [Val] vs. 2.4±2.6 preflare, 2.8±3.8 prenonflare, p=0.8953 [Dev]). Otherwise, after adjusting for multiple comparison, we did not observe differences with respect to clinical features, medication usage, or number and type of SLE-associated AutoAbs in preflare vs. prenonflare samples. The L-FRI, informed by 11 mediators (Fig. 1), significantly (p< 0.0001) differentiated preflare vs. prenonflare samples in the Val cohort, similar to that of the Dev and combined (Com) cohorts (Fig. 1), with a large ( >0.8) Cohen’s effect size, AUC >0.7 (p≤0.0003), and Spearman r ≥0.399 (p< 0.0001) vs. hSLEDAI scores at disease flare/nonflare (Fig. 1). The inclusion of 11 mediators in the L-FRI allows for varied differences between preflare vs. prenonflare across cohorts, yet with consistent differences in osteopontin, TNFRII, TNFRI, and TNF-α (Table 1). Furthermore, the L-FRI differentiates SLE patients at risk of imminent severe (S) and mild-moderate (M/M) flares vs. nonflare (Fig. 2), with increased L-FRI scores (p≤0.05), effect size (≥1.3), and AUC (≥0.843, p≤0.0002) in pre-severe flare samples across the Val, Dev, and Com cohorts (Fig. 2).

Conclusion: We verified the utility of the L-FRI, informed by 11 immune mediators, to identify SLE patients at risk of imminent lupus disease flare. Of particular interest is the ability of the L-FRI to differentiate future M/M vs. severe flare risk. A subset of mediators consistently enhanced the L-FRI to identify SLE patients who may benefit from early intervention strategies. Such an approach would be advantageous in prospective clinical trials for study participant recruitment and assessment, as well as improved management of lupus

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: M. Munroe: Progentec Diagnostics, Inc., 12, Salary Support; D. Blankenship: Progentec Diagnostics, Inc., 2; D. DeFreese: Progentec Diagnostics, Inc., 3; A. Holloway: Progentec Diagnostics, Inc., 3; M. Purushothaman: Progentec Diagnostics, Inc., 3, 4; W. DeJager: None; S. Macwana: None; J. Guthridge: None; S. Kamp: None; N. Redinger: None; T. Aberle: None; E. Chakravarty: None; C. Arriens: AstraZeneca, 1, 5, 6, Aurinia, 6, Bristol-Myers Squibb, 1, 5, Cabaletta, 1, GSK, 1, Kezar, 1, UCB, 1; Y. Li: None; H. Zeng: None; S. Dezzutti: None; P. Izmirly: None; U. Thanarajasingam: None; D. Kamen: None; J. Buyon: Bristol-Myers Squibb(BMS), 2, GlaxoSmithKlein(GSK), 2, Related Sciences, 1; J. James: Bristol-Myers Squibb(BMS), 5, GlaxoSmithKlein(GSK), 2, Novartis, 2, Progentec Biosciences, 5; E. Jupe: Progentec Diagnostics, Inc., 3.

To cite this abstract in AMA style:

Munroe M, Blankenship D, DeFreese D, Holloway A, Purushothaman M, DeJager W, Macwana S, Guthridge J, Kamp S, Redinger N, Aberle T, Chakravarty E, Arriens C, Li Y, Zeng H, Dezzutti S, Izmirly P, Thanarajasingam U, Kamen D, Buyon J, James J, Jupe E. Validation of a Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus in a Confirmatory Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/validation-of-a-flare-risk-index-informed-by-select-immune-mediators-in-systemic-lupus-erythematosus-in-a-confirmatory-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-a-flare-risk-index-informed-by-select-immune-mediators-in-systemic-lupus-erythematosus-in-a-confirmatory-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology